



VIRTUAL CONGRESS

ADVANCES IN
THE TREATMENT OF
DIGESTIVE TUMOURS

Organized by



Accredited by



Under the auspices of





INTRODUCTION

Dear friend.

On behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD), we are pleased to invite you to the 28^{th} International Symposium of our group, which this year is held virtually on the afternoons of December 15^{th} , 16^{th} and 17^{th} .

This event is an annual conference at international level in the field of digestive tumors, taking place annually for the last 27 consecutive years, and this is now an extraordinary year due to COVID-19 and the crisis which has brought to our respective health systems. But cancer is still there and digestive tumors continue to be a challenge, and progress in their knowledge and management remains an absolute necessity.

In our symposium, as in previous years, we aim to be a meeting and reference point for all oncologists and other specialists involved in the investigation and treatment of digestive tumors. As in previous editions, we will have the attendance of excellent national and international professionals to review and building consensus on our patients care advances.

The developed program contains a table dedicated to gastro-esophageal cancer, another to pancreatic tumors and NET, and another to liver tumors (including liver metastases, hepatocarcinomas, and cholangiocarcinomas). The last three tables will be dedicated to colorectal cancer, a controversy over the role of NGS in metastatic CRC, another table dedicated to prevention, localized disease and the role of liquid biopsy, and the last table dedicated to metastatic CRC.

We are positive that this programme would be of your interest. It will be an honour for us to have your active participation, which will undoubtedly contribute to increasing the educational value of the symposium.

Fernando Rivera Organizing Committee. Santander

ORGANIZATION

ORGANIZING COMMITTEE: COORDINATORS

- → Fernando Rivera Herrero
- → Carlos López López
- → Eva Martínez de Castro
- → Raquel Jimeno Maté

Servicio de Oncología Médica del Hospital Universitario Marqués de Valdecilla, Santander, Spain

ORGANIZING COMMITTEE: VOCALS

→ Enrique Aranda

Reina Sofía University Hospital Córdoba, Spain

→ Manuel Benavides

Regional University and Virgen de la Victoria Hospital Málaga, Spain

→ Alfredo Carrato

Ramón y Cajal University Hospital Madrid, Spain

→ Eduardo Díaz-Rubio

San Carlos Clinical Hospital Madrid, Spain

→ Ana Fernández Montes

University Hospital Complex of Ourense Orense, Spain

→ Pilar García Alfonso

Gregorio Marañón University Hospital Madrid, Spain

→ Begoña Graña

University Hospital Complex La Coruña, Spain

→ Cristina Grávalos

12 de Octubre University Hospital Madrid, Spain

→ Jerónimo Jiménez Castro

Virgen del Rocío Hospital Seville. Spain

→ Paula Jiménez Fonseca

Hospital Central University of Asturias Oviedo, Spain

→ Carles Pericay

Parc Taulí Sanitary Corporation Sabadell, Spain

→ Mª José Safont

General University Hospital Valencia, Spain

→ Ramón Salazar

ICO. Hospital Duran i Reynals Barcelona, Spain

→ Javier Sastre

San Carlos Clinical Hospital Madrid, Spain

→ Josep Tabernero

Vall d'Hebron University Hospital Barcelona, Spain

FACUITY

Adam, René

Centre Hépato-Biliaire, Hôpital Paul Brousse Paris, France

Álvarez Lugue, Arturo

Gregorio Marañón University Hospital Madrid, Spain

Antón, Antonio

Miguel Servet University Hospital Zaragoza, Spain

Aranda, Enrique

Reina Sofía University Hospital Córdoba, Spain

Argilés, Guillém

Vall d'Hebron University Hospital Barcelona. Spain

Benavides, Manuel

Regional University and Virgen de la Victoria Hospital Malaga, Spain

Carrato, Alfredo

Ramón y Cajal University Hospital Madrid, Spain

Cervantes, Andrés

Clinical Hospital Valencia, Spain

Cremolini, Chiara

Università di Pisa Pisa, Italy

Díaz-Rubio, Eduardo

San Carlos Clinical Hospital Madrid, Spain

Élez, Elena

Vall d'Hebron University Hospital Barcelona, Spain

Fernández Montes, Ana

University Hospital Complex of Ourense, Spain

Gallego, Javier

University General Hospital of Elche Alicante, Spain

García Alfonso, Pilar

Gregorio Marañón University Hospital Madrid, Spain

García Carbonero, Rocío

12 de Octubre University Hospital Madrid, Spain

Gómez, Carlos

12 de Octubre University Hospital Madrid. Spain

González Flores, Encarnación

Virgen de las Nieves Hospital Granada, Spain

Graña, Begoña

University Hospital Complex La Coruña, Spain

Grávalos, Cristina

12 de Octubre University Hospital Madrid, Spain

Jiménez Castro, Jerónimo

Virgen del Rocío Hospital Seville. Spain

Jiménez Fonseca, Paula

Hospital Central University of Asturias Oviedo, Spain

Lamarca, Ángela

The Christie NHS Foundation Trust and the University of Manchester Manchester, United Kingdom

López, Carlos

Marqués de Valdecilla University Hospital Santander, Spain

Macarulla, Teresa

Vall d'Hebron University Hospital Barcelona, Spain

Montagut, Clara

Hospital del Mar Barcelona, Spain

Pericay, Carles

Parc Taulí Sanitary Corporation Sabadell, Spain

Rivera, Fernando

Marqués de Valdecilla University Hospital Santander, Spain

Safont, Ma José

General University Hospital Valencia, Spain

Salazar, Ramón

ICO, Hospital Duran i Reynals Barcelona. Spain

Sartore-Bianchi, Andrea

ASST Great Metropolitan Hospital Niguarda Milan, Italy

Sastre, Javier

San Carlos Clinical Hospital Madrid, Spain

Smyth, Elizabeth C.

Cambridge University Hospitals NHS Foundation Trust Cambridge, United Kingdom

Taieb. Julien

Georges Pompidou European Hospital Paris, France

Vera. Ruth

Hospital Complex of Navarra Pamplona, Spain

SCIENTIFIC PROGRAM

MONDAY, DECEMBER 14

16:00-17:00 SATELLITE SYMPOSIUM. Sponsored by AstraZeneca. 17:15-18:15 SATELLITE SYMPOSIUM. Sponsored by Eisai-MSD.

TUESDAY, DECEMBER 15

15:15-16:15 SATELLITE SYMPOSIUM. Sponsored by Servier.

16:15-16:30 **OPENING**

18:05-18:30 Pause.

1ST TABLE. GASTROESOPHAGEAL CANCER

Moderators:	B. Graña (University Hospital Complex, La Coruña. Spain). C. Pericay (Parc Taulí Sanitary Corporation, Sabadell. Spain).
16:30-16:45	Current treatment of esophageal squamous cell carcinoma. A. Fernández Montes (University Hospital Complex of Ourense. Spain).
16:45-17:00	Molecular types of gastroesophageal adenocarcinoma and differences between East and West. C. Gómez (October 12 University Hospital, Madrid. Spain).
17:00-17:15	Current treatment of resectable gastroesophageal junction and gastric adenocarcinoma. P. Jiménez Fonseca (Hospital Central University of Asturias, Oviedo. Spain).
17:15-17:35	Immunotherapy in advanced gastroesophageal adenocarcinoma E. Smyth (Cambridge University Hospitals NHS Foundation Trust, Cambridge. United Kingdom).
17:35-18:05	Discussion.

Moderators:	A. Carrato (Ramón y Cajal University Hospital, Madrid. Spain). E. González Flores (Virgen de las Nieves Hospital, Granada. Spain).
18:30-18:45	Borderline and locally advanced pancreatic cancer: Current treatment. J. Gallego (University General Hospital of Elche, Alicante. Spain).
18:45-19:00	New approaches in the treatment of metastatic pancreatic adenocarcinoma. T. Macarulla (Vall d'Hebron University Hospital, Barcelona. Spain).
19:00-19:15	Current treatment of advanced NETs. R. García Carbonero (12 de Octubre University Hospital, Madrid. Spain).
19:15-19:45	Discussion.
19:45-19:50	Awarding TTD 2020 research aids.
19:50-20:00	Resolution of clinical case contest and presentation of the winning case.
WEDNESDA	AY, DECEMBER 16
15:15-16:15	SATELLITE SYMPOSIUM. Sponsored by Roche.
3RD TABLE. LIV	ER TUMORS: METASTASIS, CHOLANGIOCARCINOMA AND HEPATOCELLULAR CARCINOMA
Moderators:	J. Sastre (San Carlos Clinical Hospital, Madrid. Spain). R. Vera (Hospital Complex of Navarra, Pamplona. Spain).
16:15-16:30	Non-surgical locoregional management. A. Alvarez Luque (Gregorio Marañón University Hospital, Madrid. Spain).
16:30-16:50	Role of liver transplant. R. Adam (Hepato-Biliary Centre, Paul Brousse Hospital, Paris. France).

16:50-17:10 Therapeutic advances in the treatment of advanced cholangiocarcinoma.

Manchester. United Kingdom).

A. Lamarca (The Christie NHS Foundation Trust and the University of Manchester,

2ND TABLE. PANCREATIC CANCER AND NEUROENDOCRINE TUMORS (NETS)

SCIENTIFIC PROGRAM

17:10-17:25	Recent advances in the treatment of advanced hepatocellular carcinoma. C. López (Marqués de Valdecilla University Hospital, Santander. Spain).
17:25-17:55	Discussion.
17:55-18:10	Pause.

4TH TABLE, ROLE OF THE NGS IN THE METASTATIC COLORECTAL CANCER (MCRC)

Moderators:	Mª J. Safont (General University Hospital, Valencia. Spain). A. Antón (Miguel Servet University Hospital, Zaragoza. Spain).
18:10-18:15	Introduction and first vote.
18:15-18:30	In favour of NGS in mCRC. E. Élez (Vall d'Hebron University Hospital, Barcelona. Spain).
18:30-18:45	Against of NGS in mCRC. R. Salazar (ICO. Duran i Reynals Hospital, Barcelona. Spain).
18:45-18:50	Second vote.
18:50-19:10 19:10-20:10	Discussion. SATELLITE SYMPOSIUM. Sponsored by Pierre-Fabre.

THURSDAY, DECEMBER 17

15:15-16:15 SATELLITE SYMPOSIUM. Sponsored by Merck.

5TH TABLE, COLORECTAL CANCER	

Moderators:	P. García Alfonso (Gregorio Marañón University Hospital, Madrid. Spain). J. Jiménez Castro (Virgen del Rocío Hospital, Seville. Spain).
16:15-16:30	Primary and secondary prevention in colorectal cancer: cancer screening status in Spain. C. Grávalos (October 12 University Hospital, Madrid. Spain).
16:30-16:45	Current adjuvant treatment of colon cancer and future perspectives. M. Benavides (Regional University and Virgen de la Victoria Hospital, Malaga. Spain).
16:45-17:00	How can liquid biopsy help us to progress in colorectal managing? C. Montagut (Hospital del Mar, Barcelona. Spain).

17:00-17:15 Which is the best treatment for rectal cancer T3-T4 or N+?

A. Cervantes (Clinical Hospital, Valencia. Spain).

17:15-17:45 **Discussion**.

17:45-18:00 Pause.

SCIENTIFIC PROGRAM

6TH TABLE. CO	LORECTAL CANCER II (METASTATIC DISEASE)
Moderators:	E. Aranda (Reina Sofía University Hospital, Córdoba. Spain). E. Díaz-Rubio (San Carlos Clinical Hospital, Madrid. Spain).
18:00-18:20	Treatment of RAS and BRAF wild-type mCRC. Sequence of treatment, maintenance, rechallenge. Future expectations. A. Sartore-Bianchi (ASST Great Metropolitan Hospital Niguarda, Milan. Italy).
18:20-18:40	Treatment of RAS mutant mCRC: Are there prospects for future progress? J. Taieb (Georges Pompidou European Hospital, Paris Descartes University, Bys. France).
18:40-19:00	BRAF mutant mCRC and rare molecular subgroups. C. Cremolini (Università di Pisa. Department of Translational Research on New Technologies in Medicine and Surgery, Pisa. Italy).
19:00-19:15	What has immunotherapy achieved in mCRC? How to improve its results? G. Argilés (Vall d'Hebron University Hospital, Barcelona. Spain).
19:15-19:45	Discussion.
19:45-20:00	Final conclusions and closing.

GENERAL INFORMATION

ACCESS TO THE VIRTUAL PLATFORM

The attendees will be able to access the platform from the link they will receive with their confirmation of registration, along with the access codes.

ACCREDITATION

All registered attendees will be able to download the certificate of attendance and the accreditation of continuing training from the web of TTD Group (www.ttdgroup.org).

Symposium accredited with 1,1 credits by the Health Professions Continuous Formation Commission of the Autonomous Community of Cantabria.

The minimum attendance required to obtain the accreditation certificate is 80% of the total duration of the activity.

GENERAL INFORMATION

CONFERENCE SECRETARIAT

SPANISH COOPERATIVE GROUP FOR DIGESTIVE TUMOUR THERAPY

Susana Rodríguez Fernández

C/Téllez, 30 posterior. Piso 1º, Oficina 4.2 • 28007 Madrid, Spain

Tel.: +34 91 378 82 75 • Fax: +34 91 378 82 76 • Mobile Phone: +34 699 63 64 94

E-mail: simposiottd@ttdgroup.org • Website: www.ttdgroup.org

REGISTRATION FEES

General Registration fee: 405,00 € (21% VAT incl.)

Residents fee*: 303,75 € (21% VAT incl.)

*A document attesting fulfilment of resident physician condition must be provided.

Included in the registration fee: access to the scientific sessions, both live and with the possibility of participating in the controversies and discussions, as well as post-event through the platform; certificate of continuous training.

REGISTRATION FEE FORM OF PAYMENT

Registration fees can be paid by:

Checks payable to: Grupo de Tratamiento de los Tumores Digestivos.

Bank Transfer to: Grupo de Tratamiento de los Tumores Digestivos.

Bankia, Sucursal Plaza de Castilla, 3,

Account Nº: ES29.2038.1742.28.6000604214 · BIC: CAHMESMMXXX

A copy of payment must be sent to the conference secretariat together with the registration form.

Please, include the assistant name in the bank transfer.

^{*} Cancellations: Cancellations and refund request must be submitted in writing to the Conference Secretariat. There will be a refund of 50% of the total amount for cancellations received before 20 November 2020. After this date no refunds will be made. All refunds will be processed after the conference.

REGISTRATION FORM

Return the complete registration form in this program by mail or fax with payment to Spanish Cooperative Group for Digestive Tumour Therapy:

Correo: C/Téllez, 30 posterior. Piso 1º Officce 4.2 · 28007 Madrid - Spain

(Att. Susana Rodríguez Fernández)

Fax: +34 91 378 82 76 E-mail: simposiottd@ttdgroup.org

Please, keep a copy for your records.

ADDRESS INFURMATION			
Name:			
Surname:			
Address:			
Zip Code:	City:		
		e-mail:	
PAYMENT			
Registration fee:			
Total amount to be paid:			
Form of payment:			
☐ By check			
☐ By bank transfer			

Note: only forms with the corresponding payment attached will be accepted.

By filling out this form and in accordance with the provisions of Regulation (EU) 2016/679 of 27 April 2016 (GDPR) I give my consent to my data being processed under the responsibility of SPANISH COOPERATIVE GROUP FOR DIGESTIVE TUMOUR THERAPY (TTO GROUP) who will be managing the 28 International Symposium of the TTD Group. Also and if you expressly consent, we could send, even by electronic tools, upcoming conferences and/or events organized by the Data Processor. Data shall be retained while there is a mutual interest in maintaining the purpose of processing and when such purpose is no longer necessary, the data shall be deleted with the appropriate security measures to ensure the pseudonymisation or the complete destruction of them. Your data may be communicated to third parties for purposes related to the correct management of congresses, responsibility of TTD GROUP. In any other cases, data will not be disclosed to third parties, unless legally obliged to do so. I am informed that I am entitled to revoke this consent at any time and exercise the right of access, rectification, portability and erasure of my data and those of limitation and opposition to its processing by contacting Calle Téllez, 30 1 Posterior 28007 Madrid (MADRID). I am also informed that I may file a claim to the supervisory authority at www.agod.es. DPO contact: dpo@ttdgroup.org

☐ I expressly consent that TTD GROUP could send, even by electronic tools, upcoming conferences and/or events organized by the Data Processor.

SPONSORS PLATINUM





GOLD SPONSORS



SPONSORS SILVER









SPONSORS BRONZE







OTHER CONTRIBUTORS













